Annie is an experienced investment professional with over ten years of academic licensing and venture investing experience. Prior to joining Cure, Annie was an independent consultant to several VC-backed biotech companies, within oncology, gene therapy and RNA therapeutics. Annie spent over six years on the investment team at Omega Funds, where she sourced, diligenced and led investments in companies within oncology, immunology and rare diseases. Her broad investment experience ranges from company creation and academic spinouts to public company investments. Annie served as a Board Director of Trevi Therapeutics (NASDAQ:TRVI) and as a Board Observer of Anjarium Biosciences, Checkmate Pharmaceuticals (NASDAQ:CMPI, acq. by Regeneron), Ikena Oncology (NASDAQ:IKNA), Photys Therapeutics, Rectify Pharmaceuticals, and Scorpion Therapeutics.
Prior to Omega Funds, Annie was an Associate Licensing Officer at MIT’s Technology Licensing Office where she worked closely with academic researchers within the Koch Institute for Integrative Cancer Research to manage patent portfolios and negotiate license agreements. Annie also served as an independent management consultant working with Nelsen Biomedical on a variety of projects for clients within the biotechnology sector. Annie is passionate about increasing and maintaining representation of women and underrepresented minorities in venture capital. She is an active member of the B7 Women in Venture group and served as a mentor for the Venture Forward Scholarship program of VC University.
Annie earned a Ph.D. in Biomedical Engineering from the University of Michigan and a B.S. in Biomedical Engineering from the University of Virginia, where she graduated with high honors and was a member of the Tau Beta Pi Honor Society.